Med Life S.A (M) Fair Value & Analysis
Healthcare · RO · Market cap 6.0B RON
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 1.47 RON to 1.37 RON (−6.8%) since Jun 23, 2026. Share price −2.9% over the past month.
Price vs Fair Value (12 months)
12‑month range 6.52 RON – 14.28 RON · fair‑value band 0.7200 RON – 1.91 RON · the 11.36 RON price screens above the 1.37 RON fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Med Life S.A (M) currently trades at 11.36 RON, while our model-based Fair Value estimate is 1.37 RON — implying the stock looks roughly 87.9% overvalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Med Life S.A generated revenue of 3.2B RON at a net margin of 0.2%. Revenue grew 9.8% year over year. It earns a return on equity of -1.0%. Net debt stands at 1.2B RON. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Med Life S.A., a private healthcare provider, provides integrated medical services through its clinics and hospitals in Romania. The company offers outpatient units and diagnostic imaging services; consultations with general practitioners and specialists; diagnostic imaging tests; day hospitalization services; hospitalization and surgical treatment services; medical and surgical specialties; maternal and child health dedicated services; and stem cell bank. It also provides laboratory services, such as biochemistry, pathological anatomy, molecular biology and genetics, hematology, immunology, microbiology, cytology, and toxicology; healthcare packages; a range of dental services; and fitness services and wellness facilities through the Sweat Concept network and Sanopass platform. In addition, the company is involved in the development of building projects; insurance broker; rental activities; and distribution and retail sale of pharmaceutical products in specialized stores. Med Life …
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Med Life S.A reported revenue of 2.7B RON in FY2024 versus 1.1B RON in FY2020, a compound +26.0%/yr. Reported net income was 25.5M RON in FY2024, compounding −18.1%/yr from FY2020.
Open the full interactive analysis →
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$97.60 | R$115.75 | +19% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Tenet Healthcare Corporation THC | $178.75 | $300.86 | +68% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Med Life S.A (M) undervalued?
What is the fair value of M?
What is the quality score of M?
What is the revenue of Med Life S.A (M)?
What is the net profit margin of M?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.